# Lilly, Novo lock horns in India's obesity drug race - Reuters

## Metadata
| Field | Value |
|-------|-------|
| Source | Reuters |
| URL | https://news.google.com/rss/articles/CBMivwFBVV95cUxOUkR3Wkd1SmE4Z1p4SWpwbm9jZ1NNSjNfWnRzYjRTZTh5Nng2TFFrNG1SSjlaUm1FVzhuLUJTX3dkallQVTFvbWE2NmNwWUR5cU5XMWhhVzdtS1VoR3U1aXl4TnpSUXp5YU45Umx3SGZoQ3FMN1pEVFBfdXI3bHJ4TlB1Y1NVNHBtamwyVDcxZ3FHVmdGQjBJRjNKTDd2U1pZMHNMbERtMUNaWlhIMkh2ZGxiejJCenFiNVFQUkp1Zw?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 07:05 |
| Category | GLP-1 |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Novo Nordisk and Eli Lilly are expanding their obesity drug competition into the Indian market, signaling continued global growth potential for GLP-1 treatments in emerging markets.

## Key Entities
Novo Nordisk, Eli Lilly, India

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
